Reduction of susceptibility to azoles and 5-fluorocytosine and growth acceleration in Candida albicans in glucosuria

Diagn Microbiol Infect Dis. 2022 Jan;102(1):115556. doi: 10.1016/j.diagmicrobio.2021.115556. Epub 2021 Sep 25.

Abstract

Diabetes mellitus is a chronic metabolic disease characterized by hyperglycemia and glucosuria, and is a risk factor for Candida infections. To reveal the potential effects of glucosuria on Candida spp., we investigated their growth and antifungal susceptibilities in normal human urine to which glucose was added. The viable cell numbers of Candida spp. were more than 10 fold higher in the urine added 3000 mg/dL glucose than in plain urine. In antifungal susceptibility, more than 80% of Candida albicans clinical isolates increased minimum inhibitory concentrations of azoles and 5-fluorocytosine with the addition of glucose, and exceeded their breakpoints. In most of the C. albicans clinical isolates, the mRNA expression of the azole resistance genes ERG11, CDR1, CDR2, and MDR1 in the presence of glucose in urine. These observations provide valuable information about the clinical course and therapeutic effects of azoles against C. albicans infections in patients with diabetes mellitus and hyperglucosuria.

Keywords: Antifungal susceptibility; Candida species; Glucosuria.

MeSH terms

  • Antifungal Agents / pharmacology*
  • Azoles / pharmacology*
  • Candida albicans / drug effects*
  • Drug Resistance, Multiple, Fungal*
  • Flucytosine / pharmacology*
  • Glycosuria / microbiology*
  • Humans

Substances

  • Antifungal Agents
  • Azoles
  • Flucytosine